Hesperidin RCT in MS

This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.

NCT Number	NCT07452562
Lead Sponsor	Swansea University Collaborators: BioActor B.V.
Conditions	Multiple Sclerosis
Enrollment	60 participants
Start Date	2026-01-07
Primary Completion	2027-01-18 (estimated)
Study Completion	2027-01-18 (estimated)
Updated on ClinicalTrials.gov	2026-03-05